Skip to main content

Table 1 Summary of diagnostic performance of circRNA-based biomarker panel in discovery, tissue validation, serum training and validation cohorts

From: Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer

Phase

Analysis

Cohort

Control

Cancer

AUC (95% CI)

Accuracya

PPVa

Sensitivitya

Specificitya

NPV

Tissue phase

 

Discovery cohort

9

8

1 (1.00–1.00)

1 (1.00–1.00)

1 (1.00–1.00)

1 (1.00–1.00)

1 (1.00–1.00)

1 (1.00–1.00)

 

Validation cohort

28

28

0.94 (0.88–1.00)

0.88 (0.79–0.95)

1 (1.00–1.00)

0.75 (0.57–0.89)

1 (1.00–1.00)

0.8 (0.70–0.90)

Serum phase

Training

All GC vs controls

46

92

0.87 (0.82–0.93)

0.78 (0.71–0.85)

0.88 (0.82–0.94)

0.78 (0.70–0.87)

0.78 (0.65–0.89)

0.64 (0.55–0.75)

Early- stage GC vs controls

46

68

0.87 (0.80–0.93)

0.77 (0.69–0.84)

0.84 (0.77–0.92)

0.76 (0.66–0.87)

0.78 (0.65–0.89)

0.69 (0.60–0.80)

Diffuse GC vs controls

46

45

0.85 (0.77–0.92)

0.75 (0.66–0.84)

0.69 (0.61–0.78)

0.89 (0.80–0.98)

0.61 (0.48–0.76)

0.85 (0.74–0.96)

Intestinal GC vs controls

46

47

0.9 (0.84–0.96)

0.82 (0.74–0.89)

0.82 (0.73–0.91)

0.83 (0.70–0.94)

0.8 (0.70–0.91)

0.83 (0.73–0.93)

Validation

All GC vs controls

48

102

0.83 (0.77–0.90)

0.81 (0.75–0.87)

0.83 (0.79–0.89)

0.89 (0.83–0.95)

0.62 (0.48–0.75)

0.73 (0.62–0.85)

Early- stage GC vs controls

48

69

0.82 (0.74–0.89)

0.78 (0.71–0.85)

0.77 (0.70–0.83)

0.9 (0.83–0.96)

0.6 (0.46–0.73)

0.81 (0.69–0.92)

Diffuse GC vs controls

48

49

0.84 (0.77–0.92)

0.78 (0.71–0.86)

0.91 (0.82–1.00)

0.63 (0.49–0.78)

0.94 (0.85–1.00)

0.71 (0.64–0.80)

Intestinal GC vs controls

48

53

0.83 (0.75–0.91)

0.78 (0.70–0.85)

0.73 (0.67–0.81)

0.92 (0.85–0.98)

0.62 (0.50–0.75)

0.89 (0.78–0.97)

  1. GC Gastric Cancer, CI Confidence interval, PPV Positive predictive value, NPV Negative predictive value
  2. aThe value is the average of 2000 bootstrap replicates